-
Insmed (INSM) PT Lowered to $195 at RBC Capital
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
RBC Capital on Insmed's (INSM) Brinsupri Approval: 'Stock PT To $138.00, Buyers Into The Launch'
-
Insmed (INSM) PT Raised to $120 at RBC Capital
-
Insmed (INSM) PT Raised as RBC Capital Sees 'Continued Upside From Here'
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
RBC sees a buying opportunity in this biotech stock after a recent dip
-
RBC Capital Reiterates Outperform Rating on Insmed (INSM), 'Literature Analysis Suggests TPIP Has A High Likelihood of Meaningful Activity'
-
RBC Capital Starts Insmed (INSM) at Outperform
-
2Q24 U.S. biotech earnings preview
-
Pre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...)
-
After-Hours Stock Movers 06/08: (RADA) (MSTX) (EAT) Higher; (RH) (INSM) (TMH) Lower (more...)
-
Notable Analyst Rating Changes 03/11: (MT) (BBY) (NXPI) Upgraded; (AAPL) (JRCC) (NVDA) Downgraded
-
Notable 52-Week Highs and Lows of the Day 10/10: (ATVI) (CELG) (VRUS) High; (S) (ALTH) (BABY) Low
-
RBC Capital Downgrades Insmed (INSM) to Sector Perform
-
RBC Capital Starts Insmed (INSM) at Outperform; PT $1
-
Morning Movers 12/02: WBD, KKD, OREX, MCOX, RNN, INAP, PSS, MOV Higher; ARO, INSM, KR, JAS Lower
-
Insmed (INSM) Hires RBC Capital To Review Strategic Options

